Testosterone replacement therapy for late onset hypogonadism: What is the risk of inducing prostate cancer?

Prostate Cancer and Prostatic Diseases

Volumn 9, Issue 1, 2006, Pages 14-18

  Gould, Duncan C ^a   Kirby, R S ^a  

^a Prostate Centre   (United Kingdom)

Author keywords

Androgens; Dihydrotestosterone; Hypogonadism; Testosterone

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; DUTASTERIDE; FINASTERIDE; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ANDROGEN METABOLISM; ANDROPAUSE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; FOLLOW UP; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; PROSTATE; PROSTATIC NEOPLASMS; RISK FACTORS; TESTOSTERONE;

EID: 33644930859     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500839     Document Type: Review

References (45)

1. Morales A, Lunenfeld B. Investigation, treatment and monitoring of late-onset hypogonadism. The Aging Male 2002; 5: 74-86.
2. Vermeulen A, Kaufman JM. Ageing of the hypothalamopituitary-gonadal axis in men. Horm Res 1995; 43: 25-28.
3. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239.
4. World Health Organisation. Guidelines for the Use of Androgens in Men. Geneva, 1992.
5. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al. Cancer statistics, 2004. CA Cancer L Clin 2004; 54: 8-29.
6. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J et al. Human prostate cancer risk factors. Cancer 2004; 101: 2371-2490.
7. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B et al. Latent carcinoma of the prostate at autopsy in seven areas. The International Agency for research in Cancer; Lyons, France. Int J Cancer 1977; 20: 680-688.
8. Lichtenstein P, Holm NV, Verkasalo PK. Environmental and inheritable factors in the causation of cancer. N Engl J Med 2002; 343: 78-85.
9. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004; 172: S6-12.
10. Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R et al. GTSP1 CpG island hypermethylation is responsible for the absence of GTSP1 expression in human prostate cancer cells. Am J Pathol 2001; 159: 1825-1826.
11. Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL. Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: A possible link to prostate cancer evolution? J Urol 2005; 173: 1969-1974.
12. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000; 163: 824-827.
13. Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI et al. Influence of radical prostatectomy on serum hormone levels. J Urol 1998; 160: 449-453.
14. Maderbacher S, Schalzl G, Bieglmayer C, Reiter WJ, Gassner C, Berger P et al. Impact of radical prostatectomy and TURP on the hypothalamo-pituitary-gonadal hormone axis. Urology 2002; 60: 869-874.
15. Krieg M, Nass R, Tunn S. Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol and estrone in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab 1993; 77: 375-381.
16. Slater S, Oliver RTD. Testosterone: Its role in the development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging 2000; 17: 431-439.
17. Carter HB, Pearson JD, Metter EJ, Chan DW, Andres R, Fozard JL et al. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 1995; 27: 25-31.
18. Heikkila R, Aho K, Heliovaara M, Hakama M, Marniemi J, Reunanem A et al. Serum testosterone and sex hormone binding globulin concentrations and the risk of prostate carcinoma: A longitudinal study. Cancer 1999; 86: 312-315.
19. Hsing AW. Hormones and prostate cancer: What's next? Epidemiol Rev 2001; 23: 42-58.
20. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: A meta-analysis. J Clin Oncol 2000; 18: 847-853.
21. Morgentaler A, Bruning III CO, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996; 276: 1904-1906.
22. Thompson IM, Goodman PJ, Yangen CM. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 21-24.
23. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D et al. Chemoprevention of prostate cancer in men at high risk: Rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004; 172: 1314-1317.
24. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 alpha-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 2179-2184.
25. Andriole GL, Roehrbom C, Schulman C, Slawin KM, Somerville M, Rittmaster RS. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. J Urol 2004; 64: 537-541.
26. Giovannucci E, Stampfer MJ, Krithivsa K, Brown M, Dahl D, Brufsky A et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997; 94: 3320.
27. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994; 22: 3181.
28. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092-1098.
29. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: A retrospective analysis. J Clin Endocrinol Metab 1997; 82: 3793-3796.
30. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999; 84: 3469-3478.
31. Sih R, Morley JE, Kaiser FE, Perry III HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: A 12-month randomised controlled trial. J Clin Endocrinol Metab 1997; 82: 1661-1667.
32. Guay AT, Perez JB, Fitaihi WA, Vereb M. Testosterone treatment in hypogonadal men: Prostate specific antigen level and risk of prostate cancer. Endocrin Pract 2000; 6: 132-138.
33. Svetec DA, Canby ED, Thomson IM, Sabanegh Jr ES. The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction. J Urol 1997; 158: 1775-1777.
34. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerentol A Biol Sci Med Sci 2001; 56: M266-M272.
35. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G et al. Transdermal testosterone gel improves sexual function, mood, muscle strength and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2839-2853.
36. Gooren LJ. A ten-year safety study of oral androgen testosterone undecanoate. J Androl 1994; 15: 212-215.
37. Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD. Prostate specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl 2002; 23: 922-926.
38. Snyder PJ, Peachey H, Hannoush P, Loh L, Holmes JH, Dlewati A et al. Effect of testosterone on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 1966-1972.
39. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A et al. Effets of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2670-2677.
40. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ et al. Long-term testosterone gel treatment maintains beneficial effects on sexual function and mood, lean and fat mass and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 2085-2098.
41. Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M et al. Intramuscular testosterone undecanoate: Pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004; 89: 5429-5434.
42. Feneley MR, Carruthers M. PSA monitoring during testosterone replacement therapy: Low long-term risk of prostate cancer with improved opportunity for cure. Andrologia 2004; 36: 212.
43. Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk of prostate cancer: Results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 2003; 170: 2348-2351.
44. Makinen T, Tammela TL, Stenman UH, Maattanen L, Aro J, Juusela H et al. Second round results of the Finnish population-based prostate cancer screening trial. Clin Cancer Res 2004; 10: 2231-2236.
45. Liverman CT, Blazer DG (eds). Testosterone and Aging: Clinical Research Directions. Institute of Medicine of the National Academies Press: Washington DC, 2004.